The company’s board, based on the recommendation of the nomination and remuneration committee, has also appointed Agarwal as an additional director (whole-time director) of the firm, designated as executive director – finance & CFO for a period of five years, with effect from 26 February 2024. The said appointment will be subject to the approval of shareholders.

Agarwal has an experience of 20 years across a wide spectrum of finance functions including accounting, reporting, audit, controls, strategy and change management, gained across diverse industries such as consumer, services and mining. He is a Chartered Accountant, a Cost Accountant and a Company Secretary.

Pfizer is a major drug manufacturing company that focuses on a global portfolio of medical products. The company works across developed and emerging markets to advance treatments through its to segments, Pfizer Innovative Health and Pfizer Essential Health.

The pharma company's net profit tumbled 52.11% to Rs 148.96 crore in Q2 FY24 as against Rs 311.07 crore recorded in Q2 FY23. Revenue from operations declined 9.77% year on year to Rs 575.21 crore during the quarter.

Shares of Pfizer declined 1.41% to end at Rs 4,216.55 on the BSE.